Product
INM004
1 clinical trial
1 indication
Indication
Hemolytic Uremic SyndromeClinical trial
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.Status: Not yet recruiting, Estimated PCD: 2025-07-28